3TC recommended for hepatitis B.
D017277:Drug Approval; D006509:Hepatitis B / Q000188:drug therapy*; D019259:Lamivudine / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine